Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera. The company outlined plans to launch an expansive late stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results